KOL洞察报告丨神经内分泌肿瘤治疗的现状与挑战10408（英）_10页_1mb

CITELINE KOL Insights on Neuroendocrine Tumors

Key Opinion Leader Information

• Physician Specialty: Neuroendocrine Tumors (NET)
• Location: US

Drug Approvals and Efficacy

• *CAPTEM is only approved for pancreatic Neuroendocrine Tumors (NETs), not for small bowel NETs.
• Cabozantinib shows more responses than Everolimus in some cases, but further data is needed to confirm.
• Everolimus is mentioned as a comparator, but its full impact is not detailed.

Expert Analysis and Insights

• Biomedtracker provides analyses on drug likelihood of approval and market impact.
• Discussions include biomarkers and trends affecting drug development, such as alpha emitters and ADCs.
• Combination therapies are under evaluation, but their efficacy and practicality are debated. For example, from FOLFOX's perspective, it is not common practice.

Conclusion

• TheKOL emphasizes the need for more data to define biomarkers and clarify drug efficacy across different NET subtypes.

Note: This summary is based on the provided content and aims to present key information objectively.